Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partne ...

JTC Team, LLC Jenene Thomas (833) 475-8247 GRI@jtcir.com GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Identification No.) of incorporation) 2223 Avenida de la Playa, #208 La Jolla, CA 92037 (Address of principal executive offices and zip code) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 GRI BIO, INC. (Exact name of registrant as ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40034 _________________ ...

LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity being held May 17-20, 2024 in Ljubljana, Slovenia. Details of the presentations are as follows: Oral Presentation Ti ...

Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 a ...

Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation Continued advancement of an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, April 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, ...

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA. Details of the presentation are as follows: Title: Altered NKT Cell Populati ...

Financial Performance - GRI Bio reported a net loss of $13.0 million for the fiscal year ended December 31, 2023[9]. - General and administrative expenses rose to $8.2 million in 2023 from $2.0 million in 2022, with a significant portion attributed to legal and accounting fees related to a merger[13]. Research and Development - Research and development expenses increased to $3.2 million in 2023 from $0.2 million in 2022, primarily due to a $1.9 million increase related to GRI-0621 development[12]. - GRI Bio is advancing its lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), with interim data expected in H1 2024 and topline data in H2 2024[1][10]. - The company received FDA clearance for its IND application for GRI-0621, allowing it to proceed with clinical trials[3]. - GRI Bio's second asset, GRI-0803, is in development for systemic lupus erythematosus (SLE), with an IND filing expected in H1 2024[1][11]. - The company has initiated a Phase 2a biomarker study for GRI-0621, with patient screening already commenced[3][6]. Funding and Financial Strategy - The company closed a public offering generating gross proceeds of $5.5 million, extending its cash runway into Q3 2024[1][14]. Intellectual Property and Collaborations - GRI Bio has received a notice of allowance for a Canadian patent covering its proprietary NKT cell modulators[3]. - The company is collaborating with the UK Consortia to enhance recruitment for the Phase 2a biomarker study in IPF patients[3].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 GRI BIO, INC. (Exact name of registrant as specified in its charter) FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40034 | Delaware | 82-4369909 | | --- | --- | ...